Cosmos Health Share Buyback Expands to 3.87 Million Shares; Continues Open Market Repurchases
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) reported further progress under its share repurchase program of up to $5 million.
The company recently bought an additional 230,000 shares at an average price of about $0.2539, bringing total repurchases to 3,870,000 shares for approximately $758,000, with the program running through December 31, 2026.
Positive
- Additional 230,000 shares repurchased at an average price of about $0.2539
- Total 3,870,000 shares repurchased to date for approximately $758,000
- Ongoing buyback authorized up to a total of $5 million
- Program runs through December 31, 2026, allowing continued repurchases
- Management signals confidence in business trajectory via continued buybacks
Negative
- Approximately $758,000 of cash spent on share repurchases to date
Market reaction after share repurchase expansion: COSM -4.89% in the Jul 7 session
In the Jul 7 session, COSM declined 4.89%, reflecting a moderate negative market reaction. Argus tracked a peak move of +23.9% during that session. Argus tracked a trough of -26.0% from its starting point during tracking. Our momentum scanner triggered 60 alerts that day, indicating high trading interest and price volatility. Trading volume was very high at 3.3x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Buybacks Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 06 | Share repurchase expansion | Positive | +13.8% | Disclosed additional 220,000-share buyback, lifting total repurchases to 3.64M shares. |
| Jul 02 | Buyback program update | Positive | +17.6% | Reported 770,000-share repurchase, taking cumulative buybacks to 3.42M shares. |
| Jul 01 | Initial buyback execution | Positive | +9.2% | Announced initial 2.65M-share repurchase for $500,000 under new program. |
| Jun 30 | Buyback authorization | Positive | +5.5% | Authorized share repurchase program of up to $5M running through December 31, 2026. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent Cosmos Health buyback announcements have coincided with consistently positive next‑day price reactions.
Key Terms
sec rules 10b5-1 regulatory
10b-18 regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, July 07, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has repurchased an additional 230,000 shares of its common stock in the open market at an average price of approximately
The Company has now repurchased a total of 3,870,000 shares for approximately
The Company intends to continue making open market repurchases, subject to market conditions, under the program, which expires on December 31, 2026, and may be renewed at the Company's sole discretion.
Greg Siokas, CEO of Cosmos Health, stated: "We are continuing to repurchase our shares with discipline and conviction, reflecting our belief that the market continues to undervalue the strength of our platform and the trajectory of our business.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine and ongoing conflicts in the Middle East and other regions on the Company’s business, operations, and the economy in general; the Company’s ability to successfully develop and commercialize its proprietary products and technologies; changes in interest rates; changes in foreign currency exchange rates, commodity or other price inflation and deflation; our ability to issue debt on terms and at rates acceptable to us; the impact and expected outcome of investigations, inquiries, claims, and litigation; the challenges of operating in international markets; the adequacy of insurance coverage; the effect of accounting charges and of adopting certain accounting standards; the impact of legal and regulatory changes, including changes to tax laws and regulations; guidance for fiscal 2026 and beyond and financial outlook. Forward-looking statements are based on currently available information and our current assumptions, expectations and projections about future events. You should not rely on our forward-looking statements. These statements are not guarantees of future performance and are subject to future events, risks and uncertainties – many of which are beyond our control, dependent on the actions of third parties, or currently unknown to us – as well as potentially inaccurate assumptions that could cause actual results to differ materially from our historical experience and our expectations and projections. These risks and uncertainties include, but are not limited to, those described from time to time in our periodic reports filed with the SEC and available at the SEC’s website (www.sec.gov). There also may be other factors that we cannot anticipate or that are not described herein, generally because we do not currently perceive them to be material. Such factors could cause results to differ materially from our expectations. Forward-looking statements speak only as of the date they are made, and we do not undertake to update these statements other than as required by law. You are advised, however, to review any further disclosures we make on related subjects in our filings with the Securities and Exchange Commission and in our other public statements.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
